EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects

Dan-tong Liu

doi:10.1007/s13277-015-3544-6

journal article May 14, 2015

EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects

Dan-tong Liu

Tumor Biology Vol. 36 No. 7 pp. 4883-4888 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s13277-015-3544-6

Topics

No keywords indexed for this article. Browse by subject →

References

67

[1]

Monteiro LS, Delgado ML, Ricardo S, Garcez F, do Amaral B, Pacheco JJ, et al. EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival. Biomed Res Int. 2014;2014:905680. 10.1155/2014/905680

[2]

Saxena DK, Oh-Oka T, Kadomatsu K, Muramatsu T, Toshimori K. Behaviour of a sperm surface transmembrane glycoprotein basigin during epididymal maturation and its role in fertilization in mice. Reproduction. 2002;123:435–44. 10.1530/rep.0.1230435

[3]

Xiong L, Edwards 3rd CK, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci. 2014;15:17411–41. 10.3390/ijms151017411

[4]

Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol. 2007;83:283–95. 10.1016/j.yexmp.2007.08.014

[5]

Yurchenko V, Constant S, Bukrinsky M. Dealing with the family: CD147 interactions with cyclophilins. Immunology. 2006;117:301–9. 10.1111/j.1365-2567.2005.02316.x

[6]

Hanna SM, Kirk P, Holt OJ, Puklavec MJ, Brown MH, Barclay AN. A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. BMC Biochem. 2003;4:17. 10.1186/1471-2091-4-17

[7]

Huang Z, Tan N, Guo W, Wang L, Li H, Zhang T, et al. Overexpression of EMMPRIN isoform 2 is associated with head and neck cancer metastasis. PLoS One. 2014;9, e91596. 10.1371/annotation/c85feb29-046d-45f6-ba12-510f9e1d9412

[8]

Ochrietor JD, Moroz TP, van Ekeris L, Clamp MF, Jefferson SC, deCarvalho AC, et al. Retina-specific expression of 5A11/Basigin-2, a member of the immunoglobulin gene superfamily. Invest Ophthalmol Vis Sci. 2003;44:4086–96. 10.1167/iovs.02-0995

[9]

Belton Jr RJ, Chen L, Mesquita FS, Nowak RA. Basigin-2 is a cell surface receptor for soluble basigin ligand. J Biol Chem. 2008;283:17805–14. 10.1074/jbc.m801876200

[10]

Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003;54:371–89. 10.1016/s0070-2153(03)54015-7

[11]

Yao H, Teng Y, Sun Q, Xu J, Chen YT, Hou N, et al. Important functional roles of basigin in thymocyte development and T cell activation. Int J Biol Sci. 2013;10:43–52. 10.7150/ijbs.6818

[12]

Zhou XM, Zhang H, Han X. Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives. Tumour Biol. 2014;35:9523–30. 10.1007/s13277-014-2537-1

[13]

Jeong HM, Kwon MJ, Shin YK. Overexpression of cancer-associated genes via epigenetic derepression mechanisms in gynecologic cancer. Front Oncol. 2014;4:12. 10.3389/fonc.2014.00012

[14]

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. 10.3322/caac.20073

[15]

Tania M, Khan MA, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol. 2010;17:6–11. 10.3747/co.v17i5.668

[16]

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88. 10.1016/s0140-6736(13)62146-7

[17]

Tania M, Khan MA, Zhang H, Li J, Song Y. Autotaxin: a protein with two faces. Biochem Biophys Res Commun. 2010;401:493–7. 10.1016/j.bbrc.2010.09.114

[18]

Morgan Jr RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, et al. Epithelial ovarian cancer. J Natl Compr Cancer Netw. 2011;9:82–113. 10.6004/jnccn.2011.0008

[19]

Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010;102:222–9. 10.1093/jnci/djp500

[20]

du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9. 10.1093/jnci/djg036

[21]

Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, Toole BP. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res. 2009;15:7593–601. 10.1158/1078-0432.ccr-09-2317

[22]

Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician. 2000;61:1369–76.

[23]

Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16:217–30. 10.18553/jmcp.2010.16.3.217

[24]

Jiang B, Xiao S, Khan MA, Xue M. Defective antioxidant systems in cervical cancer. Tumour Biol. 2013;34:2003–9. 10.1007/s13277-013-0804-1

[25]

Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis

Mohammad H Forouzanfar, Kyle J Foreman, Allyne M Delossantos et al.

The Lancet 2011 10.1016/s0140-6736(11)61351-2

[26]

Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii27–32. 10.1093/annonc/mds268

[27]

Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–25. 10.1016/s0140-6736(03)13778-6

[28]

Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi33–8. 10.1093/annonc/mdt353

[29]

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Rafael Lozano, Mohsen Naghavi, Kyle Foreman et al.

The Lancet 2012 10.1016/s0140-6736(12)61728-0

[30]

Pessoa JN, Freitas AC, Guimaraes RA, Lima J, Dos Reis HL, Filho AC. Endometrial assessment: when is it necessary? J Clin Med Res. 2014;6(1):21–5.

[31]

Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. Mayo Clin Proc. 2008;83:97–112. 10.4065/83.1.97

[32]

Kurra V, Krajewski KM, Jagannathan J, Giardino A, Berlin S, Ramaiya N. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013;13:113–22. 10.1102/1470-7330.2013.0011

[33]

Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 2012;8, CD003915.

[34]

Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev. 2014;5, CD010681.

[35]

Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, et al. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer. 2006;95:1371–8. 10.1038/sj.bjc.6603425

[36]

Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 2005;93:199–204. 10.1160/th04-08-0536

[37]

Yang H, Chen B. CD147 in ovarian and other cancers. Int J Gynecol Cancer. 2013;23:2–8. 10.1097/igc.0b013e3182749139

[38]

Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:161–9. 10.1023/a:1022696012668

[39]

Feng L, Zhu S, Zhang Y, Li Y, Gong L, Lan M, et al. Expression and clinical significance of HAb18G/CD147 in malignant tumors. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013;29:958–61.

[40]

Jin JS, Yao CW, Loh SH, Cheng MF, Hsieh DS, Bai CY. Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol. 2006;25:140–6. 10.1097/01.pgp.0000189244.57145.84

[41]

Zhao Y, Chen S, Gou WF, Niu ZF, Zhao S, Xiao LJ, et al. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle. 2013;12:2899–913. 10.4161/cc.25950

[42]

Szubert S, Szpurek D, Moszynski R, Nowicki M, Frankowski A, Sajdak S, et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. J Cancer Res Clin Oncol. 2014;140:361–9. 10.1007/s00432-013-1569-z

[43]

Sato T, Ota T, Watanabe M, Imada K, Nomizu M, Ito A. Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. Gynecol Oncol. 2009;114:337–42. 10.1016/j.ygyno.2009.04.004

[44]

Yu W, Liu J, Xiong X, Ai Y, Wang H. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 2009;205:709–15. 10.1016/j.prp.2009.05.010

[45]

Wu Y, Zhou X, Zheng PS. Involvement of CD147 isoform-4 in the proliferation of SiHa cells: a possible molecular mechanism of cervical cancer. Oncol Rep. 2011;26:717–24.

[46]

Meng Y, Wei L, Wang J. Monitoring gene expression profile changes in endometrial cancer using cDNA microarray technology. Zhonghua Yi Xue Za Zhi. 2001;81:665–8.

[47]

Nakamura K, Kodama J, Hongo A, Hiramatsu Y. Role of emmprin in endometrial cancer. BMC Cancer. 2012;12:191. 10.1186/1471-2407-12-191

[48]

Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005;87:361–8. 10.1016/j.biochi.2004.09.023

[49]

Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis. 2002;19:697–702. 10.1023/a:1021350718226

[50]

Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–9. 10.1158/0008-5472.can-04-3605

Showing 50 of 67 references

Cited By

6

The role of microRNA-9 in ovarian and cervical cancers: An updated overview

RICCARDO DI FIORE, ROSA DRAGO-FERRANTE · 2025

European Journal of Surgical Oncolo...

Metrics

6

Citations

67

References

Details

Published: May 14, 2015
Vol/Issue: 36(7)
Pages: 4883-4888
License: View

Authors

D

Dan-tong Liu

Cite This Article

Dan-tong Liu (2015). EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects. Tumor Biology, 36(7), 4883-4888. https://doi.org/10.1007/s13277-015-3544-6

EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects

You May Also Like